Arkolith/Insider Trading/SLS/Form 4

Stergiou Angelos M.

President and CEO, DirectorSELLAS Life Sciences Group, Inc. (SLS) · full profile →Form 4 · filed Jan 14, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 10, 2025Grant(A)244K—$0859K
Jan 10, 2025Grant(A)257K—$0615K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 10, 2025Grant(A)386K—$0386K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-25-003501) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML